Starpharma Holdings Ltd 2023 AR2
The report highlights Starpharma's progress in its biopharmaceutical portfolio during the 2023 financial year. The company completed recruitment for its three Phase 2 DEP monotherapy clinical trials and expanded its partnered DEP programs with MSD and Genentech. Additionally, Starpharma achieved new registrations for its VIRALEZE antiviral nasal spray in Malaysia and Indonesia, bringing total registrations to over 35 countries. Financially, the company maintained a strong cash position of $35.2 million as of June 30, 2023, which was further bolstered by a $6.6 million settlement from Mundipharma in August 2023.
Company: Starpharma Holdings Ltd
Sector: Health Care
Country: Australia
Year: 2023
Type: AR2
Pages: 108
Starpharma Holdings Ltd
Annual Report
The report highlights Starpharma's progress in its biopharmaceutical portfolio during the 2023 financial year. The company completed recruitment for its three Phase 2 DEP monotherapy clinical trials and expanded its partnered DEP programs with MSD and Genentech. Additionally, Starpharma achieved new registrations for its VIRALEZE antiviral nasal spray in Malaysia and Indonesia, bringing total registrations to over 35 countries. Financially, the company maintained a strong cash position of $35.2 million as of June 30, 2023, which was further bolstered by a $6.6 million settlement from Mundipharma in August 2023.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jul 1, 2022 - Jun 30, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees